Overview

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

Status:
Completed

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.

Phase:

Phase 2

Details

Lead Sponsor:

Indivior Inc.

Treatments:

Arbaclofen placarbil
Baclofen